We work onFibrobodies®: Pan-fibrosis drug delivery vectors
Fibrobodies®: Pan-fibrosis drug delivery vectors
The impact of Fibrobodies®
Small, smart, and selective
Cost-effective, simple design
Suitable for diagnosis and treatment
Selective for activated myofibroblasts
What’s new at LinXis
Pipeline
Candidate | Disease | Discovery | Preclinical | Clinical phase I/II | Clinical phase II/III | |
---|---|---|---|---|---|---|
Fibrobody®-Tracer Conjugate |
All fibrosis types |
In this pivotal imaging study we will validate the targeting ability of our lead Fibrobody® against PDGFRB, in patients suffering fibrosis. At the same time, the study will help us to identify those patients that would benefit most from Fibrobody-based therapy. |
||||
Fibrobody® Drug conjugate |
Liver fibrosis, Cirrhosis |
Our lead FDC program focuses on creating Fibrobody® Conjugates based on our lead Fibrobody® against PDGFRB, that carry potent anti-fibrotic drugs to activated myofibroblasts in the liver. |
||||
Fibrobody® |
Liver fibrosis, MASH |
This exciting program explores the use Fibrobodies® as vectors for highly effective therapeutic siRNAs. These entities are notoriously ineffective in reaching the intended cells. Fibrobody®-siRNA Conjugates may take the best of both worlds. |
||||
Fibrobody® Drug conjugate |
Idiopathic pulmonary hypertension |
This program focuses on creating Fibrobody® Conjugates that carry potent anti-fibrotic and anti-contractile drugs to activated myofibroblasts in pulmonary arterial hypertension, which is a severe and unmet medical need. |
||||
Fibrobody® Drug Conjugate |
undisclosed |
We are developing novel Fibrobodies® against established and experimental targets to complement and benchmark our lead Fibrobody® against PDGFRB |
||||
Oncobody® |
Fibrotic cancers |
This program explores the concept of using Fibrobodies® as vectors to carry potent cytytoxic drugs to activated myofibroblasts in fibrotic cancers, such as pancreatic adenocarcinoma. |
Pioneering in the field of Fibrobody-Drug Conjugates
Our multidisciplinary team comprises chemists, biologists, biotechnicians and drug development specialists